机译:单细胞分析显示急性髓性白血病中Quizartinib的异质抗性
Univ Calif San Francisco Div Hematol Oncol San Francisco CA 94143 USA;
Fred Hutchinson Canc Res Ctr Seattle WA 98104 USA;
Univ Penn Div Hematol Oncol Abramson Canc Ctr Philadelphia PA 19104 USA;
Univ Calif San Francisco Div Hematol Oncol San Francisco CA 94143 USA;
Univ Calif San Francisco Div Hematol Oncol San Francisco CA 94143 USA;
Univ Calif San Francisco Div Hematol Oncol San Francisco CA 94143 USA;
Pacific Biosci Menlo Pk CA USA;
Univ Calif San Francisco Helen Diller Family Comprehens Canc Ctr San Francisco CA 94143 USA;
Univ Calif San Francisco Helen Diller Family Comprehens Canc Ctr San Francisco CA 94143 USA;
Pacific Biosci Menlo Pk CA USA;
Pacific Biosci Menlo Pk CA USA;
Johns Hopkins Univ Dept Oncol Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;
Univ Penn Div Hematol Oncol Abramson Canc Ctr Philadelphia PA 19104 USA;
Fred Hutchinson Canc Res Ctr Seattle WA 98104 USA;
Univ Calif San Francisco Div Hematol Oncol San Francisco CA 94143 USA;
机译:单细胞分析显示急性髓性白血病中Quizartinib的异质抗性
机译:造血生态位通过STAT5和AXL的缺氧依赖性上调驱动FLT3-ITD对quizartinib的急性髓细胞白血病耐药性
机译:来自骨髓基质的FGF2保护来自FLT3抑制剂Quizartinib的急性髓样白血病细胞并促进耐药性突变的获得
机译:急性髓性白血病的突畴样素揭示了对白血病的新洞察力
机译:白细胞介素1受体辅助蛋白(IL1 RAP)的治疗靶向揭示急性髓细胞白血病中的新型致癌功能。
机译:通过单细胞分析揭示了对急性髓细胞性白血病中喹唑替尼的异质耐药性
机译:单细胞分析显示急性髓性白血病中Quizartinib的异质抗性